NeoStem (NBS) announces a public offering, saying it intends to use the proceeds for working capital, including research and development of cell therapeutic product candidates, including AMR-001, plus expansion of its business units, strategic transactions and other general corporate purposes. Terms and size of the offering have not yet been disclosed. Aegis Capital is acting as sole book-running manager. Shares -8% AH.
NeoStem (NBS) announces a public offering, saying it intends to use the proceeds for working...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs